New psoriasis drug Zoryve approved. How to use & why Black American participation in clinical trials is vital for health ...

Charlie Michael Baker, 18, from Preston, Lancashire, began receiving dermal fillers in March 2024 to address insecurities ...

An influencer who was left looking “like an alien” after an adverse reaction to dermal fillers triggered a skin condition has ...

Teens with seborrheic dermatitis are most ... If you have sensitive scalp skin, it may help to shampoo less frequently. Scalp psoriasis. This autoimmune condition causes skin cells to reproduce ...

Dermatology-trained pharmacists at Boots can now provide free, in-store support on skin conditions like acne, rosacea, and ...

I tried the SickScience ShapeShift Jaw Defining Serum and it tightened, firmed, and hydrated my neck and jawline in six weeks ...

The Food and Drug Administration has approved Zoryve (roflumilast) topical foam, 0.3% for plaque psoriasis of the scalp and ...

The U.S. Food and Drug Administration has approved Arcutis Biotherapeutics' Zoryve (roflumilast) topical foam 0.3% for the ...

Roflumilast foam 0.3% applied once daily led to significantly greater clearance of scalp and body plaque psoriasis lesions and more rapid itch reduction than placebo over eight weeks.

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.